State of the art of dual therapy in 2015

Silvia Nozza, Valentina Svicher, Annalisa Saracino, Gabriella D'Ettorre, Andrea De Luca, Franco Maggiolo, Stefano Bonora, Antonio Di Biagio, Stefano Rusconi, Cristina Mussini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Dual therapy refers to combinations of two antiretroviral drugs applied in different clinical settings; they are considered and studied due to possibly reduced drug toxicities. In antiretroviral-naive patients, dual combinations have lower virologic efficacy than standard therapy; the sole efficacious regimen is lamivudine plus lopinavir/ ritonavir. Due to a higher possibility of virologic failure, these regimens are generally not allowed in this clinical setting. In antiretroviral-experienced patients, dual regimens are examined in studies with a small sample size, centered on clinical practice, and should be ritonavir-boosted protease inhibitor-based. These combinations have a good virological efficacy; combinations with the integrase inhibitor raltegravir have small sample size and demonstrated efficacy only with etravirine. Virological aspects involving dual therapy should always consider genetic barriers, particularly in simplification strategies, and ritonavir-boosted protease inhibitors are mandatory. As far as immunological aspects are concerned, nucleoside reverse transcriptase inhibitorsparing regimens have some encouraging data, probably due to the bone marrow toxicity of this class. Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. The choice of regimen should focus on specific class toxicity since dual regimens are studied in particular for improving safety and tolerability. This review will analyze different dual regimens in the clinical setting, with a peculiar focus on ameliorating toxicities and improving quality of life.

Original languageEnglish
Pages (from-to)127-134
Number of pages8
JournalAIDS Reviews
Volume17
Issue number3
Publication statusPublished - 2015

Fingerprint

Art Therapy
Ritonavir
etravirine
Protease Inhibitors
Sample Size
Integrase Inhibitors
Lopinavir
Lamivudine
RNA-Directed DNA Polymerase
Drug-Related Side Effects and Adverse Reactions
Nucleosides
Therapeutics
Bone Marrow
Quality of Life
Inflammation
Safety
Pharmaceutical Preparations

Keywords

  • Dual therapy
  • HAART
  • Simplification
  • Toxicity

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Nozza, S., Svicher, V., Saracino, A., D'Ettorre, G., De Luca, A., Maggiolo, F., ... Mussini, C. (2015). State of the art of dual therapy in 2015. AIDS Reviews, 17(3), 127-134.

State of the art of dual therapy in 2015. / Nozza, Silvia; Svicher, Valentina; Saracino, Annalisa; D'Ettorre, Gabriella; De Luca, Andrea; Maggiolo, Franco; Bonora, Stefano; Di Biagio, Antonio; Rusconi, Stefano; Mussini, Cristina.

In: AIDS Reviews, Vol. 17, No. 3, 2015, p. 127-134.

Research output: Contribution to journalArticle

Nozza, S, Svicher, V, Saracino, A, D'Ettorre, G, De Luca, A, Maggiolo, F, Bonora, S, Di Biagio, A, Rusconi, S & Mussini, C 2015, 'State of the art of dual therapy in 2015', AIDS Reviews, vol. 17, no. 3, pp. 127-134.
Nozza S, Svicher V, Saracino A, D'Ettorre G, De Luca A, Maggiolo F et al. State of the art of dual therapy in 2015. AIDS Reviews. 2015;17(3):127-134.
Nozza, Silvia ; Svicher, Valentina ; Saracino, Annalisa ; D'Ettorre, Gabriella ; De Luca, Andrea ; Maggiolo, Franco ; Bonora, Stefano ; Di Biagio, Antonio ; Rusconi, Stefano ; Mussini, Cristina. / State of the art of dual therapy in 2015. In: AIDS Reviews. 2015 ; Vol. 17, No. 3. pp. 127-134.
@article{a7ecc744294748a1843bc147f0ff5d93,
title = "State of the art of dual therapy in 2015",
abstract = "Dual therapy refers to combinations of two antiretroviral drugs applied in different clinical settings; they are considered and studied due to possibly reduced drug toxicities. In antiretroviral-naive patients, dual combinations have lower virologic efficacy than standard therapy; the sole efficacious regimen is lamivudine plus lopinavir/ ritonavir. Due to a higher possibility of virologic failure, these regimens are generally not allowed in this clinical setting. In antiretroviral-experienced patients, dual regimens are examined in studies with a small sample size, centered on clinical practice, and should be ritonavir-boosted protease inhibitor-based. These combinations have a good virological efficacy; combinations with the integrase inhibitor raltegravir have small sample size and demonstrated efficacy only with etravirine. Virological aspects involving dual therapy should always consider genetic barriers, particularly in simplification strategies, and ritonavir-boosted protease inhibitors are mandatory. As far as immunological aspects are concerned, nucleoside reverse transcriptase inhibitorsparing regimens have some encouraging data, probably due to the bone marrow toxicity of this class. Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. The choice of regimen should focus on specific class toxicity since dual regimens are studied in particular for improving safety and tolerability. This review will analyze different dual regimens in the clinical setting, with a peculiar focus on ameliorating toxicities and improving quality of life.",
keywords = "Dual therapy, HAART, Simplification, Toxicity",
author = "Silvia Nozza and Valentina Svicher and Annalisa Saracino and Gabriella D'Ettorre and {De Luca}, Andrea and Franco Maggiolo and Stefano Bonora and {Di Biagio}, Antonio and Stefano Rusconi and Cristina Mussini",
year = "2015",
language = "English",
volume = "17",
pages = "127--134",
journal = "AIDS Reviews",
issn = "1139-6121",
publisher = "Publicaciones Permanyer",
number = "3",

}

TY - JOUR

T1 - State of the art of dual therapy in 2015

AU - Nozza, Silvia

AU - Svicher, Valentina

AU - Saracino, Annalisa

AU - D'Ettorre, Gabriella

AU - De Luca, Andrea

AU - Maggiolo, Franco

AU - Bonora, Stefano

AU - Di Biagio, Antonio

AU - Rusconi, Stefano

AU - Mussini, Cristina

PY - 2015

Y1 - 2015

N2 - Dual therapy refers to combinations of two antiretroviral drugs applied in different clinical settings; they are considered and studied due to possibly reduced drug toxicities. In antiretroviral-naive patients, dual combinations have lower virologic efficacy than standard therapy; the sole efficacious regimen is lamivudine plus lopinavir/ ritonavir. Due to a higher possibility of virologic failure, these regimens are generally not allowed in this clinical setting. In antiretroviral-experienced patients, dual regimens are examined in studies with a small sample size, centered on clinical practice, and should be ritonavir-boosted protease inhibitor-based. These combinations have a good virological efficacy; combinations with the integrase inhibitor raltegravir have small sample size and demonstrated efficacy only with etravirine. Virological aspects involving dual therapy should always consider genetic barriers, particularly in simplification strategies, and ritonavir-boosted protease inhibitors are mandatory. As far as immunological aspects are concerned, nucleoside reverse transcriptase inhibitorsparing regimens have some encouraging data, probably due to the bone marrow toxicity of this class. Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. The choice of regimen should focus on specific class toxicity since dual regimens are studied in particular for improving safety and tolerability. This review will analyze different dual regimens in the clinical setting, with a peculiar focus on ameliorating toxicities and improving quality of life.

AB - Dual therapy refers to combinations of two antiretroviral drugs applied in different clinical settings; they are considered and studied due to possibly reduced drug toxicities. In antiretroviral-naive patients, dual combinations have lower virologic efficacy than standard therapy; the sole efficacious regimen is lamivudine plus lopinavir/ ritonavir. Due to a higher possibility of virologic failure, these regimens are generally not allowed in this clinical setting. In antiretroviral-experienced patients, dual regimens are examined in studies with a small sample size, centered on clinical practice, and should be ritonavir-boosted protease inhibitor-based. These combinations have a good virological efficacy; combinations with the integrase inhibitor raltegravir have small sample size and demonstrated efficacy only with etravirine. Virological aspects involving dual therapy should always consider genetic barriers, particularly in simplification strategies, and ritonavir-boosted protease inhibitors are mandatory. As far as immunological aspects are concerned, nucleoside reverse transcriptase inhibitorsparing regimens have some encouraging data, probably due to the bone marrow toxicity of this class. Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. The choice of regimen should focus on specific class toxicity since dual regimens are studied in particular for improving safety and tolerability. This review will analyze different dual regimens in the clinical setting, with a peculiar focus on ameliorating toxicities and improving quality of life.

KW - Dual therapy

KW - HAART

KW - Simplification

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84945945211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945945211&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 127

EP - 134

JO - AIDS Reviews

JF - AIDS Reviews

SN - 1139-6121

IS - 3

ER -